Un Audited financial results (Standalone and Consolidated) for the quarter and nine months ended 31.12.2025
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals reported Q3 standalone revenue of Rs 38.5 Cr with PAT of Rs 0.36 Cr (EPS Rs 0.12). For 9M FY26, standalone revenue stood at Rs 105.5 Cr with PAT of Rs 68.3 Mn. Full year standalone revenue was Rs 124.3 Cr with PAT of Rs 16.8 Cr (EPS Rs 5.13). On consolidated basis, full year revenue grew significantly to Rs 351 Cr vs Rs 163.1 Cr in prior year, with PAT of Rs 14.4 Cr (EPS Rs 4.36). However, Q3 consolidated showed a loss of Rs 6.7 Cr due to higher expenses post-acquisition. The company completed acquisition of 74.64% stake in Noumed Life Sciences (UK) for AUD 22 million and filed DRHP for IPO. Statutory auditors issued unmodified opinion. Company was previously unlisted so prior year comparatives are not available.
The company shows strong full-year revenue growth on consolidation but Q3 consolidated loss indicates integration costs from the Noumed acquisition. The IPO filing signals listing intent while significant borrowings and cash outflows for acquisition increase financial risk. Unmodified audit opinion is positive.